235 related articles for article (PubMed ID: 35821619)
1. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
[TBL] [Abstract][Full Text] [Related]
3. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
4. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
[TBL] [Abstract][Full Text] [Related]
5. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
[TBL] [Abstract][Full Text] [Related]
6. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
7. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
9. A review of combination therapy in patients with benign prostatic hyperplasia.
McVary KT
Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
11. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
12. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
13. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
15. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
Youn DH; Park J; Kim HL; Jung Y; Kang J; Jeong MY; Sethi G; Seok Ahn K; Um JY
Oncotarget; 2017 Feb; 8(6):9500-9512. PubMed ID: 27880726
[TBL] [Abstract][Full Text] [Related]
16. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
17. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
18. The role of dihydrotestosterone in benign prostatic hyperplasia.
Carson C; Rittmaster R
Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α- reductase type 2 and induced cell apoptosis.
Karunasagara S; Hong GL; Jung DY; Kim KH; Cho K; Jung JY
PLoS One; 2020; 15(8):e0236879. PubMed ID: 32790676
[TBL] [Abstract][Full Text] [Related]
20. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]